Guan Hao Biotech acquires Hangzhou Huidisen Group

With the 1,8 billion RMB acquisition, Guan Hao Biotech will become China’s second largest pharmaceutical enterprise and extend ist business into regenerative medicine, cell therapy and other drugs. Huidisen is a leader in cephalosporin production.

China Bio news release, October 24, 2016

Most popular posts: